Screener
Tarsus Pharmaceuticals, Inc. TARS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total liabilities of $264.41M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total liabilities increased by 62.8% year-over-year, from $162.38M to $264.41M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total liabilities has grown at a 105.3% compound annual growth rate (CAGR), from $5.99M to $218.73M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude